216.98
0.54%
-1.17
Dopo l'orario di chiusura:
216.98
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$218.15
Aprire:
$219.63
Volume 24 ore:
649.40K
Capitalizzazione di mercato:
$31.88B
Reddito:
$4.58B
Utile/perdita netta:
$958.38M
Rapporto P/E:
35.22
EPS:
6.16
Flusso di cassa netto:
$1.07B
1 W Prestazione:
-0.50%
1M Prestazione:
+16.63%
6M Prestazione:
+41.99%
1 anno Prestazione:
-8.37%
Resmed Inc. Stock (RMD) Company Profile
Nome
Resmed Inc.
Settore
Industria
Telefono
858-836-5000
Indirizzo
9001 Spectrum Center Boulevard, San Diego, CA
Resmed Inc. Stock (RMD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2023-09-06 | Aggiornamento | Needham | Hold → Buy |
2023-09-05 | Downgrade | UBS | Buy → Neutral |
2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2023-05-23 | Iniziato | UBS | Buy |
2023-04-14 | Iniziato | Mizuho | Buy |
2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
2022-10-12 | Iniziato | Jefferies | Hold |
2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
2022-08-15 | Downgrade | CLSA | Buy → Outperform |
2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2022-04-06 | Iniziato | Wolfe Research | Outperform |
2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
2021-08-02 | Downgrade | CLSA | Outperform → Sell |
2021-08-02 | Downgrade | Needham | Buy → Hold |
2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
2021-06-22 | Iniziato | Robert W. Baird | Neutral |
2021-06-21 | Reiterato | Needham | Buy |
2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
2021-03-16 | Aggiornamento | Needham | Hold → Buy |
2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-02-03 | Iniziato | CLSA | Underperform |
2020-01-31 | Downgrade | UBS | Buy → Neutral |
2020-01-10 | Iniziato | Oppenheimer | Perform |
2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
2019-07-16 | Downgrade | UBS | Buy → Neutral |
2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
2019-01-25 | Downgrade | Goldman | Buy → Neutral |
2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc. Borsa (RMD) Ultime notizie
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up
Zacks Investment Research
Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up
Zacks Investment Research
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline
Zacks Investment Research
Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise
Zacks Investment Research
4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts
Zacks Investment Research
Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand
Zacks Investment Research
Resmed Inc. Azioni (RMD) Dati Finanziari
Resmed Inc. (RMD) Reddito 2024
RMD ha riportato un ricavo (TTM) di $4.58 miliardi per il trimestre terminato il 2024-03-31, un +14.16% salita anno su anno.
Resmed Inc. (RMD) Reddito netto 2024
RMD l'utile netto (TTM) è stato di $958.38 milioni per il trimestre terminato il 2024-03-31, un +11.06% aumento anno su anno.
Resmed Inc. (RMD) Flusso di cassa 2024
RMD ha registrato un flusso di cassa disponibile (TTM) di $1.07 miliardi per il trimestre conclusosi con 2024-03-31, un +162.78% aumento anno su anno.
Resmed Inc. (RMD) Utile per azione 2024
L'utile per azione (TTM) di RMD è stato pari a $6.51 per il trimestre terminato il 2024-03-31, un +10.90% crescita anno su anno.
Capitalizzazione:
|
Volume (24 ore):